Plain-English translation of NCT06475989 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing two different targeted medications — plus , or — to see which one works better for people with a specific type of advanced thyroid cancer that has stopped responding to earlier treatments. Both medications are pills taken by mouth, and the study will measure how long the cancer stays under control and how well patients tolerate each treatment.
Some people with advanced thyroid cancer develop a genetic change (called BRAF V600E) that makes their cancer resistant to the first-line treatments doctors usually try. This trial exists to find out which of these two newer targeted approaches works best for these patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of the two medications as a pill by mouth every day for 28-day cycles. Throughout the study, you'll have regular visits for blood tests, CT scans, and possibly MRI scans to monitor how your cancer is responding. If your cancer starts growing again, you may be able to switch to the other medication. The study tracks how long the treatment works, any side effects you experience, and how the treatment affects your quality of life.
AI-generated summary from trial data · Aug 18, 2026 · Not medical advice
United States